194
Participants
Start Date
April 9, 2008
Primary Completion Date
July 31, 2009
Study Completion Date
September 4, 2009
Placebo
Placebo: 2 tablets taken orally twice daily
Dexpramipexole 50 mg/day
Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
Dexpramipexole 150 mg/day
Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
Dexpramipexole 300 mg/day
Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
Columbia University, Lou Gehrig MDA/ALS Research Center, New York
SUNY Upstate Medical University, Syracuse
University of Pittsburgh School of Medicine, Pittsburgh
Penn State Hershey Medical Center, Hershey
Drexel University College Of Medicine, Philadelphia
Johns Hopkins University School of Medicine, Baltimore
University of Virginia Health System, Charlottesville
University of Miami Miller School of Medicine, Miami
Vanderbilt University Medical Center, Nashville
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Kansas City
Bryan LGH Medical Center East, Lincoln
University of Arkansas for Medical Sciences, Little Rock
University of Texas Health Sciences Center of San Antonio, San Antonio
University of Colorado Health Sciences Center, Aurora
University of Utah, Salt Lake City
UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles
The Forbes Norris MDA/ALS Research Center, San Francisco
Oregon Health Sciences University, Portland
University of Washington, Seattle
Massachusettes General Hospital, Boston
Lead Sponsor
Knopp Biosciences
INDUSTRY